ACIU - AC Immune SA
| Previous Close | 14.90 |
| Open | 14.99 |
| Bid | 11.50 x 1000 |
| Ask | 15.45 x 800 |
| Day's Range | 13.04 - 14.99 |
| 52 Week Range | 6.03 - 16.35 |
| Volume | 112,438 |
| Avg. Volume | 72,061 |
| Market Cap | 790.406M |
| Beta | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings Date | May 9, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.90 |
- GlobeNewswire•9 days ago
AC Immune Announces Results of Annual General Meeting
Lausanne, Switzerland, July 6, 2018- AC Immune SA, a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the shareholders of the Company have ...
- GlobeNewswire•last month
Research Report Identifies AC Immune SA, Vipshop, Infosys, STMicroelectronics N.V., BRF S.A., and National Steel with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, June 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AC ...
- Simply Wall St.•2 months ago
What Does AC Immune SA’s (NASDAQ:ACIU) Ownership Structure Look Like?
In this analysis, my focus will be on developing a perspective on AC Immune SA’s (NASDAQ:ACIU) latest ownership structure, a less discussed, but important factor. When it comes to ownershipRead More...
- Zacks•2 months ago
Moving Average Crossover Alert: AC Immune SA (ACIU)
AC Immune SA (ACIU) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
- GlobeNewswire•2 months ago
AC Immune Reports First Quarter 2018 Financial Results and Corporate Update
Announced first-in-human study for an alpha-synuclein PET tracer for Parkinson's disease Selected Tau small molecules have entered into IND/CTA* enabling studies; Phase 1 to commence by the end of 2018 ...
- GlobeNewswire•3 months ago
AC Immune Announces Results of Extraordinary Shareholders Meeting
Lausanne, Switzerland, April 27, 2018- AC Immune SA, a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the shareholders of the Company ...
- Simply Wall St.•3 months ago
Will AC Immune SA’s (NASDAQ:ACIU) Earnings Grow Over The Next Few Years?
The most recent earnings announcement AC Immune SA’s (NASDAQ:ACIU) released in December 2017 revealed that losses became smaller relative to the prrior year’s level – great news for investors BelowRead More...
- ACCESSWIRE•3 months ago
Wired News – MediciNova Released Results of Phase-2 Clinical Trial Assessing MN-166 (ibudilast) in Methamphetamine Dependence
Stock Monitor: AC Immune Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 03, 2018 / Active-Investors.com has just released a free research report on MediciNova, Inc. (NASDAQ: MNOV ). If you want ...
- Benzinga•4 months ago
AC Immune Promising On Alzheimer's, But Light On Short-Term Catalysts, Says Credit Suisse
While AC Immune SA (NASDAQ: ACIU )’s crenezumab Alzheimer's treatment could be a breakthrough if trials prove successful, the faraway approval and launch timelines for the drug could mean the stock will ...
- Associated Press•4 months ago
AC Immune posts 4Q profit
The Lausanne, Switzerland-based company said it had net income of 7 cents per share. The biopharmaceutical company posted revenue of $16.6 million in the period. For the year, the company reported that ...
- Simply Wall St.•7 months ago
AC Immune SA (NASDAQ:ACIU) And The Healthcare Industry Prospect For 2017
AC Immune SA (NASDAQ:ACIU), a USD$718.93M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...
- Capital Cube•8 months ago
AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : November 28, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for AC Immune SA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
- Simply Wall St.•8 months ago
AC Immune SA (ACIU): Financial Strength Analysis
Zero-debt allows substantial financial flexibility, especially for small-cap companies like AC Immune SA (NASDAQ:ACIU), as the company does not have to adhere to strict debt covenants. However, it also facesRead More...
- Capital Cube•8 months ago
AC Immune SA – Value Analysis (NASDAQ:ACIU) : November 16, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives AC Immune SA a score of 38. Our analysis is based on comparing AC Immune SA with the following peers – OrganiGram Holdings Inc, Ohr Pharmaceutical, Inc., Omni Bio Pharmaceutical, Inc. and Oragenics, Inc. (OGRMF-US, OHRP-US, OMBP-US and OGEN-US). Investment Outlook AC Immune SA has a fundamental ... Read more (Read more...)
- Capital Cube•8 months ago
AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : November 15, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for AC Immune SA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
- Associated Press•8 months ago
AC Immune reports 3Q loss
On a per-share basis, the Lausanne, Switzerland-based company said it had a loss of 16 cents. Losses, adjusted for non-recurring gains, were 17 cents per share. The biopharmaceutical company posted revenue ...
